What is the NMPA drug re-registration and renewal process for already-approved products in China?

What Is the NMPA Drug Re-Registration and Renewal Process for Already-Approved Products in China?

For foreign pharmaceutical and biotech companies with products already approved in China, understanding the drug re-registration (renewal) process is essential for maintaining uninterrupted market access. Unlike some jurisdictions where drug approvals remain valid indefinitely, China’s National Medical Products Administration (NMPA) requires periodic renewal of drug registration certificates through a structured re-registration process governed by the Provisions for Drug Registration (2020) and its 2024 implementing rules.

This comprehensive FAQ covers the NMPA drug re-registration and renewal process for already-approved products, including the timeline, documentation requirements, post-marketing commitments, non-renewal consequences, and strategic considerations for foreign companies managing a China drug portfolio.

The Legal Basis: When and Why Renewal Is Required

Under Article 28 of the Provisions for Drug Registration (State Administration for Market Regulation Order No. 27, 2020), China’s drug registration certificate has a fixed validity period and must be renewed before expiration. The regulatory framework is designed to ensure that approved products maintain compliance with evolving safety, efficacy, and quality standards throughout their market lifecycle.

Certificate Validity Periods by Category

Product Category	Initial Certificate Validity	Post-Renewal Validity	Notes
Innovative Drugs (Category 1)	5 years	5 years	Each renewal granted for 5 years; no limit on number of renewals
Improved-Form Drugs (Category 2)	5 years	5 years	Same renewal cycle as innovative drugs
Generic Drugs (Category 3–4)	5 years	5 years	Requires compliance with updated consistency evaluation standards
Biological Products	5 years	5 years	May require additional post-marketing study reports
Traditional Chinese Medicines	5 years	5 years	Same cycle, but documentation requirements differ
Medical Devices (Class II/III)	5 years	5 years	Governed by separate regulations but similar renewal structure

The Renewal Timeline: When to Start

The renewal timeline is critical — missing the deadline means forfeiting the certificate and losing market access. The process unfolds according to a strict schedule:

Key Milestones

36 months before expiry: Earliest date to submit the renewal application. The NMPA accepts applications starting from this point, giving sponsors ample time to prepare the extensive dossier.
6 months before expiry: The recommended latest date to begin the renewal process. While technically possible to submit later, any delay beyond this point risks non-renewal before certificate expiration.
Certificate expiration date: If the renewal application has been submitted and is pending review, the existing certificate remains valid until the NMPA issues its decision. This “holdover” protection does NOT apply if no application was filed before expiry.
Post-expiry grace period: There is no statutory grace period. An expired certificate means the product cannot be legally manufactured, imported, sold, or distributed in China. Any unsold inventory must be removed from the market immediately.

  Critical Timing Note: Foreign drug manufacturers should begin preparing renewal dossiers at least 18 months before certificate expiry. The documentation — particularly post-marketing safety reports, manufacturing change notifications, and updated labeling — often takes 6–12 months to compile and translate. Waiting until the 6-month mark creates unnecessary regulatory risk.

The Renewal Application Process: Step by Step

Step 1: Pre-Renewal Assessment

Before preparing the application, the marketing authorization holder (MAH) should conduct a comprehensive review of the following factors that may affect renewal eligibility:

Post-marketing adverse event reporting compliance — any overdue or incomplete periodic safety update reports (PSURs) must be filed before the renewal application
Manufacturing site compliance — GMP certificates for all manufacturing sites must be valid; any warning letters or non-compliance findings must be resolved
Change management status — all approved post-approval changes (CAC/CMC variations) must be properly documented; any unapproved changes must be regularized before renewal
Compliance history — any NMPA inspections conducted during the certificate period, including outcomes of any observations
Updated standards compliance — ensure the product complies with any updated pharmacopoeia standards (e.g., Chinese Pharmacopoeia 2025 Edition)

Step 2: Compile the Renewal Dossier

The renewal application dossier includes the following components, submitted through the NMPA’s online portal (https://zwfw.nmpa.gov.cn):

Part A: Administrative Information

Renewal application form (original, with seal/signature)
Copy of the current drug registration certificate
Marketing authorization holder qualification certificate (business license, drug manufacturing license, or import drug license)
Authorization letter (for foreign companies, a notarized power of attorney designating the China agent)
China agent’s business license and drug registration agent qualification documents

Part B: Quality and Manufacturing Information

Summary of all manufacturing changes during the certificate period (including approved and unapproved changes)
Statement of GMP compliance from each manufacturing site
Copies of valid GMP certificates (or equivalent foreign GMP certifications)
List of quality-related regulatory actions, recalls, or investigations during the period
Stability data update — at least two batches of long-term stability data through the current shelf life

Part C: Safety and Efficacy Information

Periodic Safety Update Reports (PSURs) covering the full certificate period
Summary of all post-marketing safety studies conducted
Benefit-risk assessment reaffirming that the product’s benefits continue to outweigh its risks
Summary of any post-marketing clinical studies required as a condition of initial approval
Updated prescribing information (package insert) reflecting all approved changes
Patient exposure data (estimated annual patient numbers in China and globally)

Part D: Labeling and Packaging Information

Current approved labels, packaging inserts, and patient information leaflets
Updated versions incorporating any required changes since last approval
Samples of actual packaging and labeling (for physical submission)

Step 3: Submit and Pay Fees

The application is submitted electronically through the NMPA online system. The review fee structure for renewal applications differs from initial registration:

Chemical drug renewal: Approximately RMB 45,000–62,000 (USD 6,200–8,500) depending on product category
Biological product renewal: Approximately RMB 62,000–82,000 (USD 8,500–11,300)
TCM renewal: Approximately RMB 45,000–62,000
Medical device renewal: Generally lower, in the RMB 25,000–50,000 range

Fees are paid through the NMPA online payment system and are non-refundable even if the application is rejected.

Step 4: NMPA Review and Decision

The NMPA’s Center for Drug Evaluation (CDE) reviews the renewal application. The review follows a structured timeline:

Formal review: 5 working days — the CDE checks completeness of the submission
Technical review: 60 working days for standard renewals; 90 working days if the product has had significant post-marketing changes or safety issues
Supplementary review (if needed): 40 working days — the clock stops if CDE requests additional information
Total expected timeline: 65–105 working days (approximately 3–5 months) for straightforward renewals

The NMPA may issue one of the following decisions:

Approval: A renewed Drug Registration Certificate is issued with a new 5-year validity period
Conditional approval: Renewal granted subject to specified conditions (e.g., completion of a post-marketing study, submission of updated stability data)
Rejection with reasons: The NMPA identifies deficiencies that must be addressed — the applicant can resubmit after correction
Non-renewal: The product is removed from the market. This is rare but occurs for products with significant safety issues or chronic compliance failures

Special Considerations for Imported Drugs

For foreign-manufactured products marketed in China as imported drugs, the renewal process has additional requirements:

China agent continuity: The designated China agent(s) must remain valid throughout the renewal process. Any change in agent must be registered before the renewal application is submitted.
Overseas GMP compliance: Foreign manufacturers must provide evidence of continued GMP compliance in their home jurisdiction, including copies of current GMP certificates, recent inspection reports, and a statement of any significant GMP deviations during the certificate period.
Import customs compliance: Any customs-related issues (delayed clearance, product detention, testing failures) must be disclosed in the renewal application.
API and excipient sourcing: If the product uses active pharmaceutical ingredients sourced from third parties, documentation of continued compliance for those APIs is required.

Common Reasons for Renewal Delays or Rejection

Risk Factors — Watch for These:

Overdue PSUR submissions: The NMPA cross-references renewal applications with its PSUR database. Missing PSURs are the single most common cause of renewal delays (approximately 35% of all renewal-related deficiencies).
Unapproved manufacturing changes: Any change to the manufacturing process, site, or specifications that was not pre-approved by the NMPA will trigger a deficiency notice. This includes seemingly minor changes that may not require pre-approval in other jurisdictions.
Pharmacopoeia standard updates: If the drug is subject to an updated Chinese Pharmacopoeia monograph, failure to demonstrate compliance with the new standards is a common rejection reason.
Labeling discrepancies: Any discrepancy between the submitted labels and the actual marketed labels — including text, format, or content differences — will be flagged.
Incomplete stability data: At least two batches of long-term stability data through the full shelf life are required. Foreign companies often underestimate this requirement and fail to initiate stability studies early enough in the certificate period.

Strategic Considerations for Portfolio Renewal Management

Foreign biotech companies with multiple China-approved products should implement a systematic renewal management strategy:

Build a Renewal Calendar

Maintain a master calendar tracking all certificate expiry dates, with internal deadlines set at 24 months, 18 months, 12 months, and 6 months before each expiry. This prevents last-minute rushes and ensures adequate time for dossier compilation, translation, and internal review.

Inventory Your Portfolio for Renewal Decisions

Each renewal cycle provides an opportunity to assess whether the product still warrants the investment required for China market maintenance. Consider abandoning renewal for products with declining sales, generic competition that has eroded market share, or updated therapeutic guidelines that have reduced clinical utility. Maintaining a registration certificate for a product that is no longer actively marketed still requires PSUR submissions, GMP maintenance, and annual reporting — costs that may outweigh the value of keeping the door open.

Plan for Labeling and CMC Updates

The 5-year renewal cycle is the natural point to synchronize global labeling updates and CMC changes for the China market. Rather than filing separate variation applications throughout the certificate period, consolidate minor changes into a single renewal submission where regulation permits. This reduces both administrative burden and regulatory fees.

Engage a Regulatory Agent Early

Foreign companies must maintain a qualified China regulatory agent registered with the NMPA. The agent serves as the primary point of contact for the renewal process and should be engaged at least 12 months before the planned submission date. The agent must have valid registration credentials and be familiar with the specific product category.

Conclusion

The NMPA drug re-registration and renewal process is a structured, rigorous mechanism that requires proactive management well before the certificate expiry date. With a 5-year validity cycle, clear documentation requirements, and a 3–5 month review timeline, the process is manageable for foreign biotech companies that invest in systematic portfolio management and early dossier preparation.

The key to successful renewals is treating them as an ongoing lifecycle management activity rather than a periodic crisis. By maintaining up-to-date PSURs, tracking manufacturing changes, complying with pharmacopoeia updates, and keeping stability studies on schedule, foreign companies can navigate the renewal process smoothly and maintain uninterrupted market access for their products in China.